CHINO HILLS, CALIFORNIA / ACCESS Newswire / November 4, 2025 / SOHM, Inc. (OTCID:SHMN), a pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, a leader in ...

In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...

Dr. Katz's research shows how important it is for all breast cancer survivors to have access to genetic testing services, ...

The Cyclin A2 gene (CCNA2), which turns off after birth in humans, can promote cardiac repair in adult human cardiomyocytes.

Scientists are exploring leading-edge technologies that could transform how cancer is studied, detected and treated by catching it earlier, when it's more treatable and survival rates are highest.

Researchers have gained new insights into the genetic basis of rye reproduction. They have demonstrated how plants recombine ...

Chloroplasts—the "light power plants" of plant cells—are increasingly the focus of synthetic biology. These organelles house ...

Thematic indexing is Among the fastest-growing segments in the ETF market. At Bloomberg’s ETFs in Depth event in London, ...

How they’re doing it: The new company, called Preventive, is being formed to research so-called “heritable genome editing,” ...

A company’s plan to edit the genomes of human embryos worries some researchers — but it might reflect the changing attitudes towards the controversial approach.

According to Bloomberg News, Vinay Prasad, who oversees gene therapies at the FDA, said the plans will be published in early November. He foresees the approach sparking curiosity for the next wave of ...

The Duke Reading Center, which specializes in the analysis of retinal images, collaborated with Sina Farsiu, professor in the ...